The first drug to treat uveitis-related macular edema!

Bausch+Lomb and Clearside Biomedical recently announced that the U.

It is worth mentioning that Xipere is the first product approved by the US FDA to be administered by suprachoroidal space (SCS) injection, and it is also the first to be approved for the treatment of uveitis-related macular edema

Macular edema is the accumulation of fluid in the macula, causing swelling of the retina and distortion of vision.

SCS Microinjector® technology provides a unique channel for the treatment of posterior ocular diseases that often threaten vision

This approval is based on data from the Phase 3 clinical study PEACHTREE

The data showed that compared with sham controls, Xipere treatment resulted in statistically significant and clinically significant improvements in visual acuity in patients with non-infectious uveitis-related macular edema, and improvements in all anatomical sites of uveitis

Xipere (triamcinolone acetonide eye drops) is used for suprachoroidal injection.

Uveitis is a group of ocular inflammatory diseases and one of the main causes of vision loss, affecting approximately 350,000 patients in the United States and more than 1 million patients worldwide

Note: The original text has been deleted

Original source: Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis